Pipeline

our innovation

CHD-101: active for a rare genetic disease with unmet medical need; optimized next-generation cyclodextrin-drug
KS-01 is a cyclodextrin asset that CarboHyde is developing in collaboration with the University of Witwatersrand (WITS https://www.wits.ac.za/) as a breast cancer therapeutic. The partners have generated substantial supporting cellular and animal data about the asset and are now working on IND submission and clinical trial initiation.
CHD-201: Alzheimer’s disease; a unique cyclodextrin with superior pharmacokinetics designed for the purpose, proof-of-concept studies passed in various cellular and animal models
CHD-401: novel vaccine adjuvant; a tailor-made cyclodextrin to dramatically boost local T-cell related immune response, efficiency proven in different commercial vaccines
CHD-501: CarboHyde’s challenging task is to synthesize amphiphilic cyclodextrins, which will be used to formulate nanoparticles containing the RNA cargo. For more information, visit the project website: GENEGUT
CHD-601: a commercially available special cyclodextrin used as an additive in downstream vaccine production to improve the quality and yield of the biotech process

Our capabilities

Why Choose Us

HQ – Labs & Offices Located in the European Union – Budapest, Hungary The staff of researchers trained in carbohydrate chemistry, manufacturing, formulation, and analysis. We believe that the importance of serving patients is superior to our internal goals, thus CarboHyde team is happy to assist other companies in their cyclodextrin-related developments.

our innovation

Pipeline

Why Choose Us

Custom synthesis

Up-scaling

Formulation development

IP expertise

CMC expertise

Regulatory expertise

Marketing and business development expertise

Wide-spread global industrial network

Cyclodextrin/formulation analysis

Troubleshooting

Need any help?